Table 4.
Influence of disease type on engraftment
| MM (n = 12) | Lymphoma (n = 21) | Leukemia (n = 16) | SMD (n = 08) | AA (n = 08) | |
| No engraftment | 01 | 01 | 01 | ||
| Engraftment | 12 | 20 | 15 | 08 | 07 |
| Neutrophil engraftment (day) | 11.00 | 10.00 | 18.00 | 20.50 | 22.00 |
| (10.00/11.50) | (09.00/15.50) | (16.00/20.00)ab | (18.50/25.50)ab | (18.00/29.00)ab | |
| Platelet engraftment (day) | 11.00 | 13.00 | 21.00 | 23.00 | 24.00 |
| (10.00/13.00) | (10.50/16.00) | (17.00/25.00)ab | (21.00/26.50)ab | (20.00/29.00)ab | |
| OS (<6 months) | 12/12 (100%) | 19/21 (90.48%) | 14/16 (87.50%) | 08/08 (100%) | 07/08 (87.50%) |
| OS (6–12 months) | 12/12 (100%) | 17/21 (80.95%) | 12/16 (75.00%) | 05/08 (62.50%)* | 07/08 (87.50%) |
MM, multiple myeloma; SMD, syndrome myelodysplastic; AA, aplastic anemia; OS, overall survival; Neutrophil and platelet engraftment were expressed as median (lower/upper quartile).
a
Significantly different from MM.
b
Significantly different from Lymphoma.
*
OS significantly different from MM.